Transcriptional_JJ
regulation_NN
of_IN
the_DT
beta-casein_NN
gene_NN
by_IN
cytokines_NNS
:_:
cross-talk_NN
between_IN
STAT5_NN
and_CC
other_JJ
signaling_NN
molecules_NNS
._.

The_DT
beta-casein_NN
promoter_NN
has_VBZ
been_VBN
widely_RB
used_VBN
to_TO
monitor_VB
the_DT
activation_NN
of_IN
STAT_NN
-LRB-_-LRB-
signal_NN
transducer_NN
and_CC
activator_NN
of_IN
transcription_NN
-RRB-_-RRB-
5_CD
since_IN
STAT5_NN
was_VBD
originally_RB
found_VBN
as_IN
a_DT
mediator_NN
of_IN
PRL-inducible_JJ
beta-casein_NN
expression_NN
._.

However_RB
,_,
not_RB
only_RB
is_VBZ
expression_NN
of_IN
the_DT
beta-casein_NN
gene_NN
regulated_VBN
by_IN
STAT5_NN
but_CC
it_PRP
is_VBZ
also_RB
affected_VBN
by_IN
other_JJ
molecules_NNS
such_JJ
as_IN
glucocorticoid_NN
and_CC
Ras_NN
._.

In_IN
this_DT
report_NN
,_,
we_PRP
describe_VBP
the_DT
transcriptional_JJ
regulation_NN
of_IN
the_DT
beta-casein_NN
gene_NN
by_IN
cytokines_NNS
in_IN
T_NN
cells_NNS
._.

We_PRP
have_VBP
found_VBN
that_IN
the_DT
beta-casein_NN
gene_NN
is_VBZ
expressed_VBN
in_IN
a_DT
cytotoxic_JJ
T_NN
cell_NN
line_NN
,_,
CTLL-2_NN
,_,
in_IN
response_NN
to_TO
interleukin-2_NN
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
,_,
which_WDT
activates_VBZ
STAT5_NN
._.

While_IN
IL-4_NN
does_VBZ
not_RB
activate_VB
STAT5_NN
,_,
it_PRP
induces_VBZ
expression_NN
of_IN
STAT5-regulated_JJ
genes_NNS
in_IN
CTLL-2_NN
,_,
i.e._FW
beta-casein_NN
,_,
a_DT
cytokine-inducible_JJ
SH2-containing_JJ
protein_NN
-LRB-_-LRB-
CIS_NN
-RRB-_-RRB-
,_,
and_CC
oncostatin_NN
M_NN
-LRB-_-LRB-
OSM_NN
-RRB-_-RRB-
,_,
suggesting_VBG
that_IN
STAT6_NN
activated_VBN
by_IN
IL-4_NN
substitutes_VBZ
for_IN
the_DT
function_NN
of_IN
STAT5_NN
in_IN
T_NN
cells_NNS
._.

IL-2-induced_JJ
beta-casein_NN
expression_NN
was_VBD
enhanced_VBN
by_IN
dexamethasone_NN
,_,
and_CC
this_DT
synergistic_JJ
effect_NN
of_IN
Dexamethasone_NN
requires_VBZ
the_DT
sequence_NN
between_IN
-155_CD
and_CC
-193_CD
in_IN
the_DT
beta-casein_NN
promoter_NN
._.

Coincidentally_RB
,_,
a_DT
deletion_NN
of_IN
this_DT
region_NN
enhanced_VBD
the_DT
IL-2-induced_JJ
expression_NN
of_IN
beta-casein_NN
._.

Expression_NN
of_IN
an_DT
active_JJ
form_NN
of_IN
Ras_NN
,_,
Ras_NN
-LRB-_-LRB-
G12V_NN
-RRB-_-RRB-
,_,
suppressed_VBD
the_DT
IL-2-induced_JJ
beta-casein_NN
and_CC
OSM_NN
gene_NN
expression_NN
,_,
and_CC
the_DT
negative_JJ
effect_NN
of_IN
Ras_NN
is_VBZ
mediated_VBN
by_IN
the_DT
region_NN
between_IN
-105_CD
and_CC
-193_CD
in_IN
the_DT
beta-casein_NN
promoter_NN
._.

In_IN
apparent_JJ
contradiction_NN
,_,
expression_NN
of_IN
a_DT
dominant_JJ
negative_JJ
form_NN
of_IN
Ras_NN
,_,
RasN17_NN
,_,
also_RB
inhibited_VBD
IL-2-induced_JJ
activation_NN
of_IN
the_DT
promoter_NN
containing_VBG
the_DT
minimal_JJ
beta-casein_NN
STAT5_NN
element_NN
as_RB
well_RB
as_IN
the_DT
promoters_NNS
of_IN
CIS_NN
and_CC
OSM_NN
._.

In_IN
addition_NN
,_,
Ras_NN
-LRB-_-LRB-
G12V_NN
-RRB-_-RRB-
complemented_VBD
signaling_NN
by_IN
an_DT
erythropoietin_NN
receptor_NN
mutant_NN
defective_JJ
in_IN
Ras_NN
activation_NN
and_CC
augmented_VBD
the_DT
activation_NN
of_IN
the_DT
beta-casein_NN
promoter_NN
by_IN
the_DT
mutant_JJ
erythropoietin_NN
receptor_NN
signaling_NN
,_,
suggesting_VBG
a_DT
possible_JJ
role_NN
of_IN
Ras_NN
in_IN
Stat5-mediated_JJ
gene_NN
expression_NN
._.

These_DT
results_NNS
collectively_RB
reveal_VBP
a_DT
complex_JJ
interaction_NN
of_IN
STAT5_NN
with_IN
other_JJ
signaling_NN
pathways_NNS
and_CC
illustrate_VBP
that_IN
regulation_NN
of_IN
gene_NN
expression_NN
requires_VBZ
integration_NN
of_IN
opposing_JJ
signals_NNS

